Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring Feb 25 | 2023Dexcom’s Project Liberty Motives Are ConfusingPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 24 | 2023Insulet and MannKind Q4 ’22 Earnings; Novo Initiates Wegovy DTC; FDA Accepts G&L’s Bs-Glargine U100 BLA; Vadadustat Receives Positive CHMP Opinion; ATTD 2023 Key Press Releases Day 3Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 23 | 2023Apple Advances Non-Invasive Glucose Monitor; Tandem, Madrigal, Alnylam, and Teladoc Q4 ’22 Earnings; ATTD 2023 Key Press Releases Day 2Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Feb 22 | 2023Ionis Q4 ’22 Earnings; ATTD 2023 Key Press ReleasesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 21 | 2023Medtronic and Esperion CY Q4 ’22 Earnings Updates; Akebia Receives Another FDA Response for Vadadustat; Wegovy and Vadadustat CHMP Opinions; February CHMP AgendaPurchase Blast
$599
Posted in: DPP-IVi, Insulin Delivery Feb 17 | 2023Diabeloop Initiates DBL-4pen Trial; Glenmark’s Generic Onglyza Receives Tentative ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Feb 15 | 2023Biocon CY Q4 ’22 Earnings; Arrowhead Regains Rights to NASH Asset; Zydus Receives Tentative Approval for Generic InvokanaPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 13 | 2023Insulet Acquires Bigfoot’s Insulin Pump IP; Dexcom G7 Receives Medicare Reimbursement; Novo Initiates New Sema Pediatric Obesity Trial; Sanofi Completes $35M Investment in Provention; Sanofi Announces Change in R&D LeadershipPurchase Blast
$599
Posted in: Other, SGLT2i Feb 10 | 2023Novo Nordisk and Heartseed Dose First Patient in Ph1/2 LAPiS Trial of HS-001; Finerenone Receives EU Approval for FIGARO-DKD Label ExtensionPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Feb 09 | 2023AZ Q4 ’22 Earnings; Oramed to Consider M&A OpportunitiesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 08 | 2023Vertex Q4 ’22 Earnings; Dario Partners with DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Feb 07 | 2023Dexcom G7 Super Bowl DTC; Medtronic Initiates 780G+DS5 GCM Trial; Forxiga Receives EU Approval for Chronic HF; Merck Initiates Vericiguat Pediatric HF TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Feb 03 | 2023Sanofi and Regeneron Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other, SGLT2i Feb 02 | 2023Lilly, Merck, and Roche Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Feb 01 | 2023Amgen, Novartis, and Lannett Q4 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal Feb 01 | 2023Novo Nordisk Q4 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, SGLT2i Jan 31 | 2023Pfizer Q4 ’22 Earnings; Lilly Initiates Open-Label SURPASS-SWITCH-2 Study; Fractyl Health Announces Positive Week 24 REVITA-T2Di Data; Sciwind Initiates Dosing for Ph3 Ecnoglutide Trials in China; Lifescan Announces Publication of Connected BGM RWEPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
